WHEAT RIDGE, Colo., Dec 13, 2011 /PRNewswire/ -- MedEfficiency, Inc., a medical products company that is focused on the development, manufacturing, and marketing of medical devices for treating chronic wounds and lower extremity fractures, today announced that it has been awarded a Veteran's Administration (VA) Contract. Under the five year contract, MedEfficiency will be listed as a government-approved vendor.
MedEfficiency specializes in Total Contact Casting (TCC) products for off-loading diabetic foot wounds also known as diabetic foot ulcers. TCC is considered the gold standard for the treatment of diabetic foot wounds. The TCC, in conjunction with comprehensive wound care protocols, provides a dynamic approach to complete immobilization, which allows the tissue to heal without being disturbed or traumatized by repetitive injury or shear forces.
The TCC-EZ™ is a fast Total Contact Cast System, developed by MedEfficiency, which is less time consuming and less technique sensitive than traditional TCCs. The system provides a patented innovative mesh cast which constructs a one layered cast, supported by an exclusively designed outer boot that provides additional support and stability for the diabetic foot ulcer patient.
"We are extremely pleased to have been awarded the VA contract," commented Jodie Currie, CEO, MedEfficiency, "We have been providing products to wound care professionals and government healthcare agencies since 2002. With over one million diabetic patients currently in the VA system, our products provide clinically and cost-effective treatment options. The VA contract award will help to lower costs associated with diabetic foot ulcer treatments."
MedEfficiency, Inc. is a medical products company that is focused on the development, manufacturing, and marketing of medical devices for treating chronic wounds and lower extremity fractures. MedEfficiency specializes in Total Contact Casting (TCC) products, which are considered the gold standard for off-loading diabetic foot ulcers. Multiple Randomized Control Trials (RCT) of TCC indicate predictive patient outcomes ~ 90% heal rate in 6 weeks. MedEfficiency has developed innovative new products using advanced technology to change the ways these conditions are treated and result in improved clinical outcomes and more cost effective treatments. To learn more about Diabetic Foot Wounds, please visit www.medefficiency.com/diabetic_foot_wounds.html.
|SOURCE MedEfficiency, Inc.|
Copyright©2010 PR Newswire.
All rights reserved